Cravens & Co Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Cravens & Co Advisors's VRTX Position: Q3 2026 in Review
Cravens & Co Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q3 2026, buying an estimated $46.1K and bringing the position to 2,730 shares worth $1.43M. The position accounts for 0.97% of the portfolio, ranked #28.
Cravens & Co Advisors first reported a position in VRTX in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.43M in Q1 2026. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Cravens & Co Advisors held 2,730 shares of Vertex Pharmaceuticals worth $1.43M as of Q3 2026.
- Cravens & Co Advisors bought 90 Vertex Pharmaceuticals shares in Q3 2026, an estimated $46.1K.
- Vertex Pharmaceuticals made up 0.97% of Cravens & Co Advisors's portfolio in Q3 2026, its #28 holding.
- Cravens & Co Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
- Cravens & Co Advisors's Vertex Pharmaceuticals position peaked at $1.43M in Q1 2026.
- 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Cravens & Co Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.